Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Business

Dame Kate Bingham Celebrates ‘Astonishing’ $3bn Deal for EyeBio

by May 30, 2024
May 30, 2024
Dame Kate Bingham Celebrates ‘Astonishing’ $3bn Deal for EyeBio

In a landmark deal for the biotech industry, EyeBio, a London-based startup co-founded by Dame Kate Bingham, has been acquired by US pharmaceutical giant Merck, known as MSD in the UK, for up to $3bn (£2.36bn).

This acquisition is poised to revolutionise treatments for blindness.

Merck has committed to an initial payment of $1.3bn (£1bn) for EyeBio, with an additional $1.7bn contingent on achieving certain milestones. The rapid success of EyeBio, which raised just $130m since its founding in August 2021, has been described as “astonishing” by Dame Kate Bingham.

Bingham’s venture capital firm, SV Health Investors, established EyeBio in collaboration with scientists David Guyer and Tony Adamis. Since its inception, Dame Kate has served as the company’s chairman, leveraging her prominent profile as one of the key figures behind the UK’s successful Covid-19 vaccine rollout.

Dame Bingham was instrumental in leading the UK’s Vaccine Taskforce in early 2020, earning a damehood for her efforts in securing Covid-19 vaccines, which enabled the UK to become the first Western country to begin vaccinating its population in late 2020. She stepped down from this role at the end of 2020 and returned to her position at SV Health Investors as a managing partner.

The acquisition by Merck is expected to accelerate the development of EyeBio’s innovative treatments for eye diseases. EyeBio’s primary focus has been on diabetic macular oedema and age-related macular disease, two of the most prevalent causes of blindness in the Western world. Dame Kate told the Financial Times that the company’s drugs have the potential to “revolutionise the treatment” of these conditions.

David Guyer, EyeBio’s Chief Executive and President, highlighted the benefits of the acquisition: “As a subsidiary of Merck, EyeBio will be positioned to tap into the resources and infrastructure needed to support the clinical, regulatory, and commercial development of these candidates and help bring them to patients worldwide.”

Merck’s acquisition of EyeBio aligns with its strategy to enhance its drug pipeline, particularly as its blockbuster cancer drug nears the end of its patent. This deal not only signifies a major advancement for EyeBio but also underscores the critical role of innovative biotech companies in transforming healthcare outcomes.

Read more:
Dame Kate Bingham Celebrates ‘Astonishing’ $3bn Deal for EyeBio

0
FacebookTwitterGoogle +Pinterest
previous post
Millennial Homeownership Reaches 12-Year High Amid Rising Wages
next post
UK Households with No Work Reach 12-Year High Amid Labour Crisis

You may also like

Bosses warn Sunak scaling back HS2 will hurt...

September 24, 2023

Fraudulent Bounce Back loan application prosecutions – what...

October 25, 2022

The overall situation has been determined. The hottest...

December 19, 2024

Bank of England may cut rates more aggressively...

October 4, 2024

16-24-year-olds see employment jobs spike as living costs...

February 14, 2023

Small businesses postponing investment plans as they cope...

August 24, 2023

10 UX UI Design Stats and Trends that...

April 2, 2024

US tariff war disrupts UK luxury exports as...

April 24, 2025

Getting to Know You: Jesse Swash, Co-Founder of...

August 8, 2024

Pressure mounts on Lloyds to release full report...

November 11, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • DAVID MARCUS: Zany Zohran endorsement is existential choice for Hakeem Jeffries

      July 26, 2025
    • FTC firings take spotlight in Trump’s fight to erase independence of agencies

      July 26, 2025
    • DNI Tulsi Gabbard declassified Trump-Russia docs: Here’s what they say

      July 26, 2025
    • Trump signs rescissions package, closes out week with trip to Scotland

      July 26, 2025
    • CHARLIE KIRK: Republicans must seize Gen Z moment or risk losing an entire generation

      July 26, 2025
    • Technology in Hospitality: Innovations Shaping Guest Experiences

      July 26, 2025

    Categories

    • Business (8,580)
    • Investing (2,151)
    • Politics (16,208)
    • Stocks (3,228)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved